Journal article:
Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases

No Thumbnail Available
Date
2018
Editors
Berger, Nathan A
Besson, Valerie C
Boulares, A Hamid
Chiarugi, Alberto
Clark, Robert S
Curtin, Nicola J.
Cuzzocrea, Salvatore
Dawson, Ted M
Szabo, Csaba
relationships.isEditorOf
Contact
Journal ISSN
Electronic ISSN
ISBN
Bibliographical data
Publisher
Series
DOI (citable link)
ArXiv-ID
International patent number
Link to the license
Project
EU project number
Open Access publication
Collections
Restricted until
Title in another language
Research Projects
Organizational Units
Journal Issue
Publication type
Journal article
Publication status
Published
Abstract
The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors.
Summary in another language
Subject (DDC)
570 Biosciences, Biology
Keywords
Published in
British journal of pharmacology ; 175 (2018), 2. - pp. 192-222. - ISSN 0366-0826. - eISSN 1476-5381
Conference
Review
undefined / . - undefined, undefined. - (undefined; undefined)
Cite This
ISO 690BERGER, Nathan A, Valerie C BESSON, A Hamid BOULARES, Alexander BÜRKLE, Alberto CHIARUGI, Robert S CLARK, Nicola J. CURTIN, Salvatore CUZZOCREA, Ted M DAWSON, Csaba SZABO, 2018. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. In: British journal of pharmacology. 175(2), pp. 192-222. ISSN 0366-0826. eISSN 1476-5381. Available under: doi: 10.1111/bph.13748
BibTex
@article{Berger2018Oppor-41708,
  year={2018},
  doi={10.1111/bph.13748},
  title={Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases},
  number={2},
  volume={175},
  issn={0366-0826},
  journal={British journal of pharmacology},
  pages={192--222},
  author={Berger, Nathan A and Besson, Valerie C and Boulares, A Hamid and Bürkle, Alexander and Chiarugi, Alberto and Clark, Robert S and Curtin, Nicola J. and Cuzzocrea, Salvatore and Dawson, Ted M and Szabo, Csaba}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/41708">
    <dc:contributor>Cuzzocrea, Salvatore</dc:contributor>
    <dc:creator>Dawson, Ted M</dc:creator>
    <dc:language>eng</dc:language>
    <dc:contributor>Dawson, Ted M</dc:contributor>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/41708"/>
    <dc:contributor>Boulares, A Hamid</dc:contributor>
    <dcterms:issued>2018</dcterms:issued>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2018-03-07T09:55:25Z</dc:date>
    <dc:contributor>Clark, Robert S</dc:contributor>
    <dc:rights>terms-of-use</dc:rights>
    <dc:creator>Chiarugi, Alberto</dc:creator>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Bürkle, Alexander</dc:creator>
    <dc:contributor>Berger, Nathan A</dc:contributor>
    <dc:contributor>Curtin, Nicola J.</dc:contributor>
    <dcterms:abstract xml:lang="eng">The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors.</dcterms:abstract>
    <dc:creator>Cuzzocrea, Salvatore</dc:creator>
    <dc:contributor>Bürkle, Alexander</dc:contributor>
    <dc:contributor>Besson, Valerie C</dc:contributor>
    <dc:contributor>Szabo, Csaba</dc:contributor>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/41708/1/Berger_2-uyiw5z27na2s1.pdf"/>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2018-03-07T09:55:25Z</dcterms:available>
    <dc:creator>Clark, Robert S</dc:creator>
    <dc:creator>Curtin, Nicola J.</dc:creator>
    <dc:creator>Besson, Valerie C</dc:creator>
    <dcterms:title>Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases</dcterms:title>
    <dc:creator>Berger, Nathan A</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Szabo, Csaba</dc:creator>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Boulares, A Hamid</dc:creator>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/41708/1/Berger_2-uyiw5z27na2s1.pdf"/>
    <dc:contributor>Chiarugi, Alberto</dc:contributor>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
  </rdf:Description>
</rdf:RDF>
Internal note
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Contact
URL of original publication
Test date of URL
Examination date of dissertation
Method of financing
Comment on publication
Alliance license
Corresponding Authors der Uni Konstanz vorhanden
International Co-Authors
Bibliography of Konstanz
Yes
Refereed
Yes
Link to research data
Description of supplementary data